World of DTC Marketing

OCTOBER 6, 2020

WHAT’S THIS ABOUT THEN : Researchers are rushing to launch clinical trials of experimental vaccines against the coronavirus, and treatments for COVID-19. We are now seeing impacts on clinical-trial continuity in all the regions where we conduct clinical studies.”.

Patients 180

Patients Physicians Networking Pharmaceutical 180

pharmaphorum

APRIL 8, 2020

This pharmaphorum webinar will take place on 8th April and comes as the COVID-19 outbreak has exposed the challenges pharmaceutical companies face as they race to develop a coronavirus vaccine. Thrown into even sharper relief than usual are the needs faced by all vaccine trials to balance study speed, data accuracy and patient experience.

Recruitment 52

Recruitment Patients Pharmaceutical 52

World of DTC Marketing

AUGUST 5, 2020

When a pharma company like “Moderna has not been living up to contractual obligations to disclose the percentage of taxpayer dollars that are funding its coronavirus vaccine project, but the pharmaceutical company tells Axios that federal money makes up “100% funding of the program.”

Pharma 180

Pharma Management Patients Leads 180

European Pharmaceutical Review

AUGUST 17, 2023

The National Institutes of Health (NIH) has chosen contract development, and manufacturing organisation (CDMO) Exothera SA to develop the manufacturing process for its intranasal vaccine against SARS-CoV-2 coronavirus to treat COVID-19. MHRA authorises new COVID-19 vaccine What will the intranasal vaccine manufacturing project involve?

Manufacturing 91

Manufacturing Medicine Physicians Safety 91

Pharmaceutical Technology

JUNE 24, 2022

Developed utilising Novavax’s recombinant nanoparticle technology to generate antigen obtained from the coronavirus spike (S) protein, the vaccine is also formulated with the company’s saponin-based Matrix-M adjuvant.

Food and Drug Administration 105

Food and Drug Administration FDA Engineering Food 105

World of DTC Marketing

NOVEMBER 23, 2020

The “courage” headline thanks people who participated in the clinical trials this vaccine. A new Gallup poll finds that 58% of Americans said they would get vaccinated against the coronavirus if there was an FDA-approved vaccine available right now at no cost. But, it’s more than that.

Distribution 188

Distribution FDA Pharma Leads 188

Pharmaceutical Technology

AUGUST 1, 2022

Furthermore, the parties will collaborate on the joint development of systems that accelerate the latest designs into clinical usage. The human health product candidates of GreenLight are currently in the pre-clinical stage.

Marketing 98

Marketing Pharmaceutical Manufacturing 98

World of DTC Marketing

SEPTEMBER 7, 2021

Politico reported Thursday that in recent private discussions with lawmakers, pharmaceutical lobbyists have explicitly invoked the industry’s role in the rapid development of coronavirus vaccines as an argument against proposed fixes for out-of-control prescription drug costs and other regulations. But there’s a rub.

Government 209

Government Prescription Healthcare Healthcare 209

pharmaphorum

MAY 27, 2020

Insights on the impact of COVID-19 for pharma and biotech companies and considerations for a post-coronavirus new normal in life sciences and healthcare. It will also discuss the UK response to the emergency, clinical trials and how digital health has met the COVID-19 challenge for healthcare professionals, patients and industry.

Healthcare 40

Healthcare Healthcare Pharma Patients 40

pharmaphorum

JUNE 23, 2022

The suit – filed in a Massachusetts district court – claims that Paxlovid (nirmatrelvir and ritonavir) infringes its 11,358,953 patent which covers “compounds and pharmaceutically acceptable salts which inhibit coronavirus replication activity, and methods of treating a coronavirus infection” and was awarded earlier this month.

Distribution 52

Distribution Pharma Sales Pharmaceutical 52

European Pharmaceutical Review

AUGUST 26, 2022

Moreover, the company said despite having many different options, Pfizer and BioNTech copied Moderna’s approach to encode for the full-length spike protein in a lipid nanoparticle formulation for a coronavirus.” ” But why sue now?

Sales 92

Sales Medicine Marketing Government 92

Pharmaceutical Technology

AUGUST 15, 2022

The updated, Omicron-containing bivalent vaccine that acts on two coronavirus variants is indicated as a booster dose for active immunisation for the prevention of Covid-19 in people of this age group. The latest MHRA decision is based on findings from the Phase II/III clinical trial, where the mRNA-1273.214 vaccine met all primary endpoints.

Side effects 85

Side effects Safety Government Pharmaceutical 85

World of DTC Marketing

MARCH 4, 2021

million were in countries where more than half the population is overweight” A study of thousands of hospitalized coronavirus patients in the New York City area has found that nearly all of them had at least one major chronic health condition, and most — 88 percent — had at least two. Hypertension, obesity, and diabetes were common.

Insurance 197

Insurance Prescription Leads Pharma 197

Pharmaceutical Technology

JUNE 10, 2023

CIGB-128 is under clinical development by Center for Genetic Engineering and Biotechnology and currently in Phase I for Brain Tumor. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Engineering 40

Engineering Marketing 40

Pharmaceutical Technology

JUNE 10, 2023

CIGB-128 is under clinical development by Center for Genetic Engineering and Biotechnology and currently in Phase I for Brain Tumor. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Engineering 40

Engineering Marketing 40

pharmaphorum

JANUARY 27, 2023

AZ also said it is testing a follow-up to Evusheld in the SUPERNOVA phase 1/3 clinical trial for COVID-19 pre-exposure prophylaxis in an immunocompromised population, with results due in the second half of 2023. That antibody has been shown to neutralise “all SARS-CoV-2 variants tested to date”, according to the drugmaker.

FDA 128

FDA Sales Marketing Medical 128

pharmaphorum

APRIL 23, 2020

You can listen to our March webinar here: [link] Focus During the April instalment, our expert panel will discuss: •Assessing the pharmaceutical market impact of COVID-19 •The UK clinical trials on COVID-19: navigating uncharted waters •Genomics: research in the time of COVID-19 •Knowledge sharing: the COVID-19 experience from a US perspective •Getting (..)

Pharma 40

Pharma Government Healthcare Healthcare 40

Pharmaceutical Technology

FEBRUARY 14, 2023

Edoxaban tosylate is under clinical development by Daiichi Sankyo and currently in Phase II for Atrial Fibrillation. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Prescription 40

Prescription Pharmaceutical products Networking Pharmaceutical 40

pharmaphorum

JANUARY 19, 2023

Representing a significant milestone for Vaxxas, it builds on its pre-clinical portfolio into mRNA vaccines, with the potential to expand the company’s vaccine technology pipeline across a number of diseases, including COVID-19. In February 2022, the UK said it would pledge £160 million to CEPI to speed up vaccine development.

Transportation 99

Transportation Government Manufacturing 99

Pharmaceutical Technology

JUNE 8, 2023

Publication of these results in Nature Communications supports the scientific rigor of our work and potential clinical utility of our next-generation vaccine platform for the prevention of infectious diseases, including coronaviruses, such as Covid-19,” said Andrew Allen, Chief Executive Officer of Gritstone.

Safety 52

Safety Management 52

pharmaphorum

NOVEMBER 25, 2022

“It would be comparable to first-generation SARS-CoV-2 mRNA vaccines, which were targeted to the original Wuhan strain of the coronavirus,” said Hensley. ” Hensley et al say they are currently designing human clinical trials of the vaccine candidate. are not similar.”

Prospecting 105

Prospecting Manufacturing Medicine Leads 105

pharmaphorum

JULY 7, 2022

There were plenty of reasons to be cautious about the rapid development of a COVID-19 vaccine; a previous attempt to develop a vaccine against a different type of coronavirus actually increased cats’ risk of developing the disease. The institute also led and funded early-stage clinical research into the vaccine candidate.

Government 84

Government 84

pharmaphorum

SEPTEMBER 22, 2022

Le Vert says Osivax’s technology differs, however, as it attacks the virus’ T-cells, making the vaccine more effective in the long term, and that clinical trials have shown promise. Over 800 subjects have been recruited for four clinical trials, with 72 to 300 subjects in the various trials.

Training 78

Training Specialization Recruitment Management 78

Pharmaceutical Technology

JUNE 23, 2022

And while various coronavirus strains both old and new continue to take a heavy toll on the world, the unprecedented speeds at which the Pfizer/BioNTech, Moderna, and AstraZeneca vaccines and therapeutics such as dexamethasone were developed and distributed served to save millions more. Decentralised trials continue to be in-demand.

Patients 52

Patients Pharmaceutical Distribution Healthcare 52

Every Ancillary

MAY 14, 2021

Cons: Programs take some diligence on behalf of the clinic which can be challenging for some. No sector of the medical ancillary space has undergone more change in the past couple of years than that of clinical laboratory sales. That being said, the clinical laboratory market is expected to see growth of nearly 40% by 2028.

Medical sales 52

Medical sales Medical Sales Insurance 52

Pharmaceutical Technology

JUNE 4, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Leads 98

Leads Pharmaceutical Medicine Medical 98

Clarivate

DECEMBER 8, 2021

The report documents the worldwide surge of research on the SARS-CoV-2 coronavirus and its clinical course. Most strikingly, the 2021 edition conveys the rapid and pervasive impact of COVID-19 on global research. However, the pertinent Research Fronts are not confined to biological and medical subfields.

Specialization 98

Specialization Leads Government Medical 98

Pharmaceutical Technology

JUNE 4, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Pharmaceutical 52

Pharmaceutical Leads Medical 52

Pharmaceutical Technology

MAY 24, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. By means of geographic reach, Redbiotec holds the top position.

Medicine 52

Medicine Pharmaceutical Leads Prescription 52

Pharmaceutical Technology

MAY 8, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Leads 52

Leads Pharmaceutical Engineering Medicine 52

Pharmaceutical Technology

APRIL 18, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Pharmaceutical 59

Pharmaceutical Leads Medical Medicine 59

Salesforce

MAY 19, 2020

Last month, at EyeforPharma, North America’s largest commercial pharma event (which became a virtual event due to the coronavirus), I listened to industry leaders address what’s impacting pharma today. Will this have a lasting impact on clinical trials? Here are some examples: Clinical trials.

Pharma 52

Pharma Physicians Healthcare Healthcare 52

European Pharmaceutical Review

OCTOBER 30, 2023

Vaccitech is leveraging multiple platforms to address an array of infectious diseases, including Middle East Respiratory Syndrome Coronavirus (MERS-CoV), a member of the SARS/CoV-2 family of betacoronaviruses that has previously demonstrated its potential to cause an epidemic with the 2015 South Korea outbreak.

Distribution 99

Distribution Manufacturing Pharmaceutical Government 99

World of DTC Marketing

JULY 12, 2021

According to a report on CNN.com “Pfizer said it is seeing waning immunity from its coronavirus vaccine and says it is picking up its efforts to develop a booster dose that will protect people from variants.” My doctor said she is waiting for more clinical data and has already had patients ask about a booster shot.

FDA 292

FDA Doctors Media Physicians 292

European Pharmaceutical Review

JULY 11, 2022

The novel coronavirus vaccine has been developed at Caltech and The University of Oxfor d. How the novel coronavirus vaccine works. 8 vaccine approach is being used for development of a novel coronavirus vaccine [Credit: Coalition for Epidemic Preparedness Innovations (CEPI)]. 8” nanoparticles. . The mosaic?8

Manufacturing 96

Manufacturing Engineering Leads Medicine 96

Referral MD

JULY 28, 2022

Embracing new technology is not only the need of the hour, but it can also help your healthcare business grow quickly amid the coronavirus outbreak by accelerating the pace at which you achieve your end goal.

Healthcare 52

Healthcare Healthcare Media Patients 52

Clarify Health

AUGUST 26, 2020

According to polling results shared from the Kaiser Family Foundation (KFF), nearly half of adults (48%) say they or someone in their household have postponed or skipped medical care due to the coronavirus outbreak. This drastic decline in utilization caused many plans to miss their MLR targets for the year. billion last year.

Insurance 52

Insurance Medical Networking Management 52